TEVA
Teva Pharma Industries Ltd ADR
NYSE: TEVA · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC
$34.63
+0.20% today
Updated 2026-06-12
Market cap
$40.32B
P/E ratio
25.84
P/S ratio
2.32x
EPS (TTM)
$1.34
Dividend yield
—
52W range
$15 – $37
Volume
6.2M
Teva Pharma Industries Ltd ADR (TEVA) Financial Forecast & Price Target 2030
Research-backed projections from analyst consensus, management guidance, and sector analysis.
Research-backed TEVA price target 2030 projection accounting for share dilution, balance sheet debt, and time value of money.
Current price
$34.63
Today
Analyst consensus
$41.78
+20.65% · 12M
2030 Base
$9.52
-72.51% future
NPV today
$6.34
@ 9% WACC
13 analysts:
9 Buy0 Hold1 Sell
Management guidance
Teva has reaffirmed its 2026 financial outlook and committed to reaching 2027 financial targets while advancing toward an investment-grade credit profile. Management is executing a 'Pivot to Growth' strategy, shifting from generics to branded pharmaceuticals (Austedo, Ajovy, Uzedy) with CNS portfolio growth of 42.1% YoY in Q1 2026. CEO guidance targets improved margins and branded drug dominance, though specific revenue dollar targets for 2026-2030 have not been publicly disclosed.
Sources: Management guidance, analyst consensus, sector analysishigh confidence
TEVA · Teva Pharma Industries Ltd ADR · Revenue & price projection · 2023–2030E
Actual / 2030 target Projected revenue Base case price Bull to bear range
Bear case (2030)
$9.52
NPV today: $6.34
Base case (2030)
$9.52
NPV today: $6.34
Bull case (2030)
$29.11
NPV today: $19.40
WallStSmart.com
TEVA financial forecast · Research-backed projections
| Metric | 2025 | 2026 (E) | 2027 (E) | 2028 (E) | 2029 (E) | 2030 (E) ★ |
|---|---|---|---|---|---|---|
| Revenue | $17.3B | $17.1B | $18.1B | $19.5B | $21.2B | $23.1B |
| Revenue growth | 4.3% | -0.9% | 5.5% | 8.0% | 8.7% | 9.0% |
| Net margin | — | 16.5% | 20.6% | 23.2% | 25.7% | 27.3% |
| EPS | $2.37 | $2.41 | $3.18 | $3.85 | $4.62 | $5.35 |
| Diluted shares | — | 1168M | 1171M | 1175M | 1177M | 1180M |
| Net debt | — | $15.95B | $15.05B | $14.08B | $13.02B | $11.87B |
| P/S multiple | — | 1.0x | 1.0x | 1.0x | 1.0x | 1.0x |
| Implied price (base) | — | $0.98 | $2.56 | $4.61 | $6.95 | $9.52 |
★ 2030E is the model's terminal target year. Implied price = (Revenue × P/S − Net debt) ÷ Diluted shares.
Scenario detail · Three drivers, three outcomes
| 2030E driver | Bear | Base | Bull |
|---|---|---|---|
| Revenue | $23.1B | $23.1B | $23.1B |
| P/S multiple | 1.0x | 1.0x | 2.0x |
| Diluted shares | 1180M | 1180M | 1180M |
| Net debt | $11.87B | $11.87B | $11.87B |
| Implied P/E † | 2x | 2x | 5x |
| 2030 Price | $9.52 | $9.52 | $29.11 |
| NPV @ 9% | $6.34 | $6.34 | $19.40 |
† Implied P/E: Multiples remain elevated across all three scenarios because TEVA is valued primarily on revenue scale during its growth phase, not near-term earnings power. Lower P/E in the bear case reflects multiple compression, but the absolute level stays high since 2030E still represents a hypergrowth-to-mature transition year.
EV to per-share bridge · How we get to $9.52 base case
TEVA catalysts and risks
Growth catalysts
+ Emalex Biosciences acquisition ($900M) adding ecopipam for Tourette syndrome, expanding CNS pipeline
+ FDA approvals for biosimilars (PONLIMSI denosumab, Xolair omalizumab filing) driving higher-margin revenue
+ CNS portfolio expansion: Austedo, Ajovy, Uzedy showing 42%+ YoY growth; schizophrenia once-monthly injectable (TEV-749) NDA accepted
+ Fitch investment-grade upgrade (BBB-) improving financing flexibility and validating turnaround narrative
+ Shift from generic-heavy to branded/specialty portfolio reducing pricing pressure and improving margins
Key risks
- Generic drug pricing compression continues despite branded portfolio growth; historical 5Y revenue CAGR only 0.7%
- Concentrated CNS portfolio risk: Austedo faces potential pricing/reimbursement pressures; overreliance on 3-4 key products
- High debt load ($53.14B enterprise value vs $41.6B market cap) limits financial flexibility despite Fitch upgrade
- Biosimilar execution risk: timing and adoption of new launches (Prolia, Xolair) uncertain; competitive landscape intense
- R&D execution risk: pipeline candidates (ecopipam, TEV-749) must achieve regulatory approval and commercial adoption
- Insider selling activity (CFO, EVP sales in May 2026) may signal limited upside conviction at current valuations
Methodology · Teva Pharma Industries Ltd ADR 2030 stock forecast model
Teva Pharma Industries Ltd ADR 2030 price target is calculated using WallStSmart's research model. Revenue projections are derived from analyst consensus across 13 Wall Street analysts, management guidance from the latest earnings call, and sector growth forecasts. The model is built on five core components:
| 1. Share dilution | Projected from per-ticker schedule of SBC + equity raise activity, compounding year by year (1% cumulative for TEVA by 2030) |
| 2. Net debt | EV minus net debt yields equity value; debt projected from capex cycle trajectory ($11.87B by 2030) |
| 3. Time value | NPV calculated using 9% WACC (CAPM: beta 0.863) |
| 4. Multiple framework | P/S compresses with scale: bear 1.0x / base 1.0x / bull 2.0x |
| 5. Scenario design | Bull/Base/Bear vary revenue, margin, shares, debt, and multiple independently |
WallStSmart research model · Not financial advice · Past performance is not indicative of future results · Last researched: May 21, 2026.
TEVA price target FAQ
What is the TEVA price target for 2030?
WallStSmart's Teva Pharma Industries Ltd ADR 2030 base case is $9.52 per share, with a bull case of $29.11 and bear case of $9.52. The NPV of the base case discounted to today at 9% WACC is $6.34.
How is the Teva Pharma Industries Ltd ADR 2030 stock forecast calculated?
The TEVA 2030 projection multiplies projected revenue by a growth-adjusted P/S multiple to derive enterprise value, subtracts projected net debt to get equity value, then divides by diluted shares outstanding accounting for dilution from stock-based compensation and equity raises.
Why does the TEVA price target account for dilution?
Teva Pharma Industries Ltd ADR is projected to grow diluted share count from 1164M to 1180M by 2030 (a 1% increase) through stock-based compensation and capital raises. Ignoring this would inflate the price target by approximately 1%.
What is the analyst consensus on TEVA stock?
13 analysts cover TEVA with an average 12-month price target of $41.78. The 2030 projection extends this framework with longer-horizon assumptions including dilution and time value of money.